Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting
April 09, 2024 16:30 ET
|
Auron Therapeutics Inc.
Preclinical data from lead program addressing AURIGIN-identified KAT2A/B target showed significant cell state shift and tumor growth inhibition across multiple primary cancer models AURIGIN overview...
Auron Announces Poster Presentations at 2024 AACR Annual Meeting
March 06, 2024 08:00 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic...
Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform
February 08, 2024 08:00 ET
|
Auron Therapeutics Inc.
AUTX-703 has demonstrated potent growth inhibition in preclinical models of solid tumors and a hematological malignancy An overview of the Company’s AURIGIN platform to be presented at the American...
Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA
August 10, 2023 11:08 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Auron Therapeutics, a platform-based, product-driven biotechnology company focused on discovering and developing novel cancer therapies using its...
Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer
August 01, 2023 07:30 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Auron Therapeutics, a platform-based, product-driven biotechnology company focused on developing novel cancer therapies that target cellular...
Auron Therapeutics announces $48 million Series A financing to drive novel oncology pipeline leveraging a machine learning, multi-omics-based platform
July 20, 2022 08:00 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular...
Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers
January 27, 2021 08:00 ET
|
Auron Therapeutics Inc.
WELLESLEY, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing differentiation therapies for treating cancer, today announced...